SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review.

Yulei Chen; Jinjin Lin; Peiyi Zheng; Minjie Cao; Tengchuan Jin

Return

SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review.

Author: Yulei CHEN ¹ ; Jinjin LIN ¹ ; Peiyi ZHENG ² ; Minjie CAO ¹ ; Tengchuan JIN ²
Author Information

1. College of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, Fujian, China.
2. School of Basic Medical Sciences, University of Science and Technology of China, Hefei 230027, Anhui, China.
Publication Type:Review
Keywords: COVID-19; SARS-CoV-2; monoclonal antibody; nanobody; receptor binding domain
MeSH: Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; Humans; Peptidyl-Dipeptidase A/metabolism*; Protein Binding; SARS-CoV-2; Single-Domain Antibodies; Spike Glycoprotein, Coronavirus/metabolism*
From: Chinese Journal of Biotechnology 2022;38(9):3173-3193
CountryChina
Language:Chinese
Abstract: Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with strong contagiousness, high susceptibility and long incubation period. cell entry by SARS-CoV-2 requires the binding between the receptor-binding domain of the viral spike protein and the cellular angiotensin-converting enzyme 2 (ACE2). Here, we briefly reviewed the mechanisms underlying the interaction between SARS-CoV-2 and ACE2, and summarized the latest research progress on SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies, so as to better understand the development process and drug research direction of COVID-19. This review may facilitate understanding the development of neutralizing antibody drugs for emerging infectious diseases, especially for COVID-19.